Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ophthalmic
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Senju
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Dry Eye Disease|Keratoconjunctivitis Sicca|Dry Eye Syndromes
Phase 2: Conduct Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| DELTA-1 Study | P3 |
Completed |
Keratoconjunctivitis Sicca|Dry Eye Syndromes|Dry Eye Disease |
2019-03-15 |
8% |
2019-04-17 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
| SJP-0035/2-02 | P2 |
Completed |
Conduct Disorder |
2017-05-03 |
2019-03-21 |
Treatments |
|
| SJP-0035/2-01 | P2 |
Completed |
Conduct Disorder |
2015-08-04 |
2021-03-30 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/23/2024 |
News Article |
Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease |